Professional Documents
Culture Documents
Calprotectin Test
BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of
calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration
(FDA) and is now commercially available in the US.
Amherst, NH, June 14, 2018 --(PR.com)-- BÜHLMANN Laboratories AG, is proud to announce it has
received United States Food and Drug Administration (FDA) 510(k) clearance of its BÜHLMANN
fCAL® ELISA. The BÜHLMANN fCAL® ELISA is an in vitro diagnostic assay intended for the
quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in
the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative
colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction
with other laboratory and clinical findings.
Due to the high prevalence of gastrointestinal disease and challenges of current treatment pathways, the
use of a non-invasive inflammation bio-marker such as calprotectin is essential in helping physicians
evaluate patients in a timely manner. The use of a biomarker for patient care demands that the test be
accurate and reproducible over long periods of time - one of the key characteristics of the BÜHLMANN
fCAL® ELISA assay.
KT Park, MD, MS, Chair of Clinical Care and Quality, NASPGHAN and Co-Director, Stanford
Children's IBD Center at Stanford University School of Medicine stated, “Screening fecal calprotectin
prior to diagnostic endoscopy is a cost-effective approach to differentiate IBS versus IBD. The growing
body of research — especially in the area of IBD — will continue to inform clinical practice
and reliance on noninvasive biomarkers. I am mindful of the numerous correlation and validation studies
already published using the BÜHLMANN fCAL® ELISA. When considering the recent FDA clearance
of BÜHLMANN's calprotectin in the U.S., assay reliability and precision data are important
considerations. And expanding the marketplace of calprotectin with high-quality assay options should
enhance patient care."
In a multi-site clinical study, the BÜHLMANN fCAL® ELISA, which has excellent precision and
reproducibility, was demonstrated to be a valuable diagnostic aid in the diagnosis of IBD and in the
discrimination between IBD and IBS.
Visit www.buhlmannlabs.com to learn more about this assay, and overall performance.
Page 1/3
PR.com Press Release Distribution Terms of Use
BÜHLMANN GanglioCombi™ products for neuroimmunology, and a variety of Melatonin Assays.
Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
BUHLMANN Diagnostics Corp
Stacy Smith
844-300-9799
Contact via Email
www.buhlmannlabs.com
info@buhlmannlabs.com
Page 3/3
PR.com Press Release Distribution Terms of Use